Efficacy and toxicity of antibody-drug conjugates in the treatment of metastatic urothelial cancer: A scoping review
- PMID: 35973928
- DOI: 10.1016/j.urolonc.2022.07.006
Efficacy and toxicity of antibody-drug conjugates in the treatment of metastatic urothelial cancer: A scoping review
Abstract
Introduction: Metastatic urothelial cancer (mUC) is an aggressive disease with limited overall survival and treatment options. Antibody-drug conjugates (ADCs) were designed with the intent to deliver potent cytotoxic drugs selectively to antigen-expressing tumor cells by linking cytotoxins to monoclonal antibodies (mAbs) and have emerged as new treatment options in mUC, mainly in chemotherapy (CT) and immune-checkpoint inhibitors (ICI)-exposed patients. We aimed to perform a scoping review to assess activity, efficacy, treatment-related adverse events (TRAEs), and impact on quality of life of ADCs in mUC.
Methods: A review of the literature was performed in January 2022 using Pubmed and Embase databases according to the recommendations of the Joanna Briggs Institute. The search method involved querying for the terms "bladder carcinoma" or "urothelial carcinoma" with any of the following: "enfortumab vedotin" (EV), "sacituzumab govitecan" (SG), antibody-drug conjugate. Only prospective clinical trials were included.
Results: Ultimately, eleven clinical trials with 1417 patients were selected for inclusion, and five drugs were identified: enfortumab vedotin (EV), sacituzumab govitecan (SG), disitamab vedotin (RC48-ADC), ASG-15ME (anti-SLITRK6), and trastuzumab deruxtecan. The different ADCs have been tested mainly in phase 1 or phase 2 trials, as monotherapy or in combination with ICI. Response rate ranged from 27% with SG in previously treated patients to 73.3% with EV plus pembrolizumab in cisplatin-ineligible patients as first-line treatment. The phase 3 trial, EV-301, confirmed EV superiority over investigator-chosen CT after failure to platinum-based CT and ICI, improving overall survival (12.88 vs. 8.97 months; HR 0.70; 95% CI, 0.56-0.89; P=0.001). TRAEs of any grade occurred in more than 90% of patients in phase 2 or 3 trials, with high rates of grade 3 ≥ events ranging from 51.4 to 73.5% in different trials. TRAEs of particular interest related to EV were rash, neuropathy, and hyperglycemia. SG was associated with diarrhea and hematologic toxicity. Data from phase 2 and 3 trials of EV suggest no impact on quality of life but an improvement in pain symptoms compared to the control arm.
Conclusions: ACDs represent a new therapeutic option for the treatment of mUC. Level-1 evidence has already been achieved by EV in the post-CT and post-ICI settings. A high incidence of potential adverse events was observed in phase 2 and 3 trials, including rash, neutropenia, hematologic toxicity, and neuropathy. Clinicians should be aware of possible adverse events and their optimal management.
Keywords: Antibody-drug conjugates; Metastatic urothelial cancer; Toxicity.
Copyright © 2022 Elsevier Inc. All rights reserved.
Similar articles
-
The Double Antibody Drug Conjugate (DAD) phase I trial: sacituzumab govitecan plus enfortumab vedotin for metastatic urothelial carcinoma.Ann Oncol. 2024 Jan;35(1):91-97. doi: 10.1016/j.annonc.2023.09.3114. Epub 2023 Oct 21. Ann Oncol. 2024. PMID: 37871703 Clinical Trial.
-
The Rapidly Evolving Landscape of First-Line Targeted Therapy in Metastatic Urothelial Cancer: A Systematic Review.Oncologist. 2021 Aug;26(8):e1381-e1394. doi: 10.1002/onco.13827. Epub 2021 Jun 11. Oncologist. 2021. PMID: 34028134 Free PMC article.
-
Mechanisms of Resistance to Antibody-Drug Conjugates.Int J Mol Sci. 2023 Jun 2;24(11):9674. doi: 10.3390/ijms24119674. Int J Mol Sci. 2023. PMID: 37298631 Free PMC article. Review.
-
Antibody-drug conjugates for urothelial carcinoma.Urol Oncol. 2023 Oct;41(10):420-428. doi: 10.1016/j.urolonc.2023.06.006. Epub 2023 Jul 6. Urol Oncol. 2023. PMID: 37419845 Review.
-
Targeted Molecular Therapeutics for Bladder Cancer-A New Option beyond the Mixed Fortunes of Immune Checkpoint Inhibitors?Int J Mol Sci. 2020 Oct 1;21(19):7268. doi: 10.3390/ijms21197268. Int J Mol Sci. 2020. PMID: 33019653 Free PMC article. Review.
Cited by
-
Antibody-Drug Conjugates in the Treatment of Genitourinary Cancers: An Updated Review of Data.Curr Oncol. 2024 Apr 19;31(4):2316-2327. doi: 10.3390/curroncol31040172. Curr Oncol. 2024. PMID: 38668075 Free PMC article. Review.
-
Antibody-drug conjugates in urothelial carcinoma: scientometric analysis and clinical trials analysis.Front Oncol. 2024 Mar 14;14:1323366. doi: 10.3389/fonc.2024.1323366. eCollection 2024. Front Oncol. 2024. PMID: 38665947 Free PMC article. Review.
-
Expression of HER2 in high-grade urothelial carcinoma based on Chinese expert consensus and the clinical effects of disitamab vedotin-tislelizumab combination therapy in the treatment of advanced patients.Front Pharmacol. 2024 Feb 22;15:1355081. doi: 10.3389/fphar.2024.1355081. eCollection 2024. Front Pharmacol. 2024. PMID: 38455962 Free PMC article.
-
Targeted therapies in bladder cancer: signaling pathways, applications, and challenges.MedComm (2020). 2023 Dec 15;4(6):e455. doi: 10.1002/mco2.455. eCollection 2023 Dec. MedComm (2020). 2023. PMID: 38107059 Free PMC article. Review.
-
Navigating the Rapidly Evolving Advanced Urothelial Carcinoma Treatment Landscape: Insights from Italian Experts.Curr Oncol Rep. 2023 Nov;25(11):1345-1362. doi: 10.1007/s11912-023-01461-x. Epub 2023 Oct 19. Curr Oncol Rep. 2023. PMID: 37855848 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical